{
    "clinical_study": {
        "@rank": "141127", 
        "arm_group": [
            {
                "arm_group_label": "Sotatercept 1.0 mg/kg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sotatercept 2.0 mg/kg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Sotatercept 0.5 mg/kg", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to determine a safe, tolerable and effective dose of\n      sotatercept that results in the greatest frequency of improvement of anemia in patients\n      diagnosed with low- or intermediate-1 risk MDS or non-proliferative chronic myelomonocytic\n      leukemia (CMML)."
        }, 
        "brief_title": "Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Anemia", 
            "Myelodysplastic Syndromes (MDS)", 
            "Chronic Myelomonocytic Leukemia (CMML)", 
            "Low to Intermediate-1 MDS"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Leukemia", 
                "Leukemia, Myelomonocytic, Chronic", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Leukemia, Myelomonocytic, Acute"
            ]
        }, 
        "detailed_description": {
            "textblock": "Following enrollment of the initial 3 arms; additional cohorts of 20 patients for\n      intermediate cohorts (not to exceed 2.0 mg/kg) may be added at the time of dose escalation\n      up to 1.0 mg/kg and up to 2.0 mg/kg (eg, 0.75 mg/kg or 1.5 mg/kg respectively) based on\n      assessment by the Steering Committee of available safety and efficacy data when at least six\n      subjects have at least three cycles of treatment in the current dose level."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Men and women \u2265 18 years of age\n\n          -  Documented diagnosis of myelodysplastic syndromes (MDS) or non-proliferative chronic\n             myelomonocytic leukemia (CMML), White blood cells (WBC) \u2264 13,000 /mm3, World Health\n             Organization (WHO)) that meets International Prognostic Scoring System (IPSS)\n             criteria for low or intermediate-1 risk disease\n\n          -  Anemia defined as requiring transfusion of >= 2 units of red blood cells (RBCs)\n             within 84 days of enrollment for hemoglobulin (Hgb) <= 9.0 g/dL\n\n          -  No response or loss of response to Erythropoiesis-Stimulating Agents (ESAs) or\n             erythropoetin (EPO) > 500 mU/ml\n\n          -  No response or loss of response to no greater than 2 prior lines of treatment for\n             myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia\n             (CMML) not including ESAs or lines discontinued due to intolerance.\n\n          -  Eastern Cooperative Group (ECOG) score \u22642. Adequate renal function reflected by\n             creatinine < 1.5 X Upper Limit of the Normal (ULN) and creatinine clearance of 50\n             ml/min according to Cockcroft-Gault formula\n\n          -  Total bilirubin \u22643.0 mg/dL\n\n          -  Aspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT) &\n             alanine aminotransferase (ALT)/serum glutamic pyruvic (SGPT) \u22643.0 x Upper Limit of\n             Normal (ULN)\n\n          -  Free of metastatic malignancy (other than myelodysplastic syndromes (MDS)) for \u22652\n             years\n\n        Exclusion Criteria:\n\n          -  Pregnant or breast feeding women and males who do not agree to use condom during the\n             sexual contact with females of childbearing potential.\n\n          -  Major surgery within 30 days\n\n          -  Incomplete recovery or incomplete healing of wounds from previous surgery\n\n          -  Heart failure \u22653 (New York Heart Association(NYHA))\n\n          -  Thromboembolic or myocardial infarction event within 6 months\n\n          -  Subjects requiring ongoing anticoagulant therapy during course of study.  Aspirin is\n             allowed.\n\n          -  Concurrent  anti-cancer cytotoxic chemotherapy\n\n          -  History of severe allergic or anaphylactic reaction or hypersensitivity to\n             recombinant protein\n\n          -  Known positive for human immunovirus (HIV) or infectious hepatitis type C or active\n             infectious hepatitis type B.\n\n          -  Clinically significant anemia unrelated to myelodysplastic syndromes (MDS)\n\n          -  Thrombocytopenia (<30,000/uL)\n\n          -  Uncontrolled hypertension\n\n          -  Treatment with another investigational drug or device within 28 days prior to Day 1\n\n          -  Prior Exposure to sotatercept (ACE-011)\n\n          -  Any serious medical condition, lab abnormality or psychiatric illness"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01736683", 
            "org_study_id": "ACE-011-MDS-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sotatercept 1.0 mg/kg", 
                "description": "Sotatercept 1.0 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles", 
                "intervention_name": "Sotatercept", 
                "intervention_type": "Drug", 
                "other_name": "(ActRIIA-IgG1Fc)"
            }, 
            {
                "arm_group_label": "Sotatercept 2.0 mg/kg", 
                "description": "Sotatercept 2.0 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles", 
                "intervention_name": "Sotatercept", 
                "intervention_type": "Drug", 
                "other_name": "(ActRIIA-IgG1Fc)"
            }, 
            {
                "arm_group_label": "Sotatercept 0.5 mg/kg", 
                "description": "Sotatercept 0.5 mg/kig subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles", 
                "intervention_name": "Sotatercept", 
                "intervention_type": "Drug", 
                "other_name": "(ActRIIA-IgG1Fc)"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "ACE-011", 
            "anemia", 
            "dose-ranging", 
            "intermediate-1 risk myelodysplastic syndromes", 
            "low risk myelodysplastic syndromes (MDS)", 
            "multicenter", 
            "open-label", 
            "parallel", 
            "phase 2", 
            "randomized", 
            "Sotatercept", 
            "Non-proliferative chronic myelomonocytic leukemia (CMML)", 
            "hemoglobin", 
            "transfusions"
        ], 
        "lastchanged_date": "February 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80218"
                    }, 
                    "name": "Rocky Mountain Cancer Centers"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33602"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21231"
                    }, 
                    "name": "Johns Hopkins University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana-Farber Cancer Institute/Brigham and Women's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lake Success", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11020"
                    }, 
                    "name": "North Shore-LIJ Health System Monter Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic Foundation"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "The University of Texas, MD Anderson Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Round Rock", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78681"
                    }, 
                    "name": "Texas Oncology"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tyler", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75702"
                    }, 
                    "name": "Texas Oncology"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23502"
                    }, 
                    "name": "Virginia Oncology Associates"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yakima", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98902"
                    }, 
                    "name": "Yakima Valley Memorial Hospital/North Star Lodge"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bobigny", 
                        "country": "France", 
                        "zip": "93009"
                    }, 
                    "name": "Centre Hospitalier Universitaire H\u00f4pital Avicenne"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "CHRU de Lille -H\u00f4pital Claude Huriez Service des Maladies du Sang"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanes", 
                        "country": "France", 
                        "zip": "44000"
                    }, 
                    "name": "CHU De Nantes"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris Cedex", 
                        "country": "France", 
                        "zip": "75001"
                    }, 
                    "name": "H\u00f4pital Cochin"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France", 
                        "zip": "13273"
                    }, 
                    "name": "Centre de Recherche en Cancerologie de Marseille- Institute Paoli Calmettes"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rouen Cedex 1", 
                        "country": "France", 
                        "zip": "76038"
                    }, 
                    "name": "Centre Henri Becquerel"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "CHU Purpan"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Randomized, Phase 2, Parallel, Dose-ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low- or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML).", 
        "overall_contact": {
            "email": "cpowell@celgene.com", 
            "last_name": "Christopher Powell", 
            "phone": "908-673-2259"
        }, 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Abderrahmane Laadem", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "HI-E (for subjects that require a transfusion of <4 units of RBCs) is an increase \u22651.5 g/dL Hgb sustained over a period \u22658 weeks in the absence of RBC transfusion; or HI-E (for subjects that require a transfusion of  \u22654 units of RBCs) is a decrease \u22654 units of RBCs transfused over a period of 8 weeks", 
            "measure": "Erythroid Hematological Improvement (HI-E)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01736683"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of participants with adverse events", 
                "measure": "Adverse Event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 3 years"
            }, 
            {
                "description": "The time between randomization (for Part 1)/start of therapy (for Part 2) and the date the start of HI-E", 
                "measure": "Red Blood Cell (RBC) Transfusion Independence", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 weeks"
            }, 
            {
                "description": "The length of time between first and last assessment of HI-E", 
                "measure": "Duration to Erythroid Hematological Improvement (HI-E)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 weeks"
            }, 
            {
                "description": "Time from baseline until progression to AML", 
                "measure": "Time to progression to Acute Myeloid Leukemia (AML)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Time from baseline until progression to events of higher risk MDS", 
                "measure": "Time to progression to events of higher risk MDS", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Number of participants who survive without progressing.", 
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Number of participants who survive", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Maximum observed concentration in serum", 
                "measure": "Pharmacokinetics-Cmax", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks"
            }, 
            {
                "description": "Time to maximum observed concentration serum", 
                "measure": "Pharmacokinetics-Tmax", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks"
            }, 
            {
                "description": "Area under the plasma concentration-time curve", 
                "measure": "Pharmacokinetics- AUC", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}